Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2)
Issued Date
2022-10-01
Resource Type
eISSN
27723747
Scopus ID
2-s2.0-85139688548
Journal Title
JACC: Asia
Volume
2
Issue
5
Start Page
519
End Page
537
Rights Holder(s)
SCOPUS
Bibliographic Citation
JACC: Asia Vol.2 No.5 (2022) , 519-537
Suggested Citation
Chiang C.E., Chao T.F., Choi E.K., Lim T.W., Krittayaphong R., Li M., Chen M., Guo Y., Okumura K., Lip G.Y.H. Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2). JACC: Asia Vol.2 No.5 (2022) , 519-537. 537. doi:10.1016/j.jacasi.2022.06.004 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85480
Title
Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 2)
Author's Affiliation
Siriraj Hospital
National Yang Ming Chiao Tung University
National University Health System
Jiangsu Province Hospital
General Hospital of People's Liberation Army
National Yang-Ming University Taiwan
Liverpool Heart and Chest Hospital
Aalborg University
Seoul National University Hospital
Saiseikai Kumamoto Hospital
Veterans General Hospital-Taipei
National Yang Ming Chiao Tung University
National University Health System
Jiangsu Province Hospital
General Hospital of People's Liberation Army
National Yang-Ming University Taiwan
Liverpool Heart and Chest Hospital
Aalborg University
Seoul National University Hospital
Saiseikai Kumamoto Hospital
Veterans General Hospital-Taipei
Other Contributor(s)
Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with substantial increases in the risk for stroke and systemic thromboembolism. With the successful introduction of the first non-vitamin K antagonistdirect oral anticoagulant agent (NOAC) in 2009, the role of vitamin K antagonists has been replaced in most clinical settings except in a few conditions for which NOACs are contraindicated. Data for the use of NOACs in different clinical scenarios have been accumulating in the past decade, and a more sophisticated strategy for patients with AF is now warranted. JACC: Asia recently appointed a working group to summarize the most updated information regarding stroke prevention in AF. The aim of this statement is to provide possible treatment options in daily practice. Local availability, cost, and patient comorbidities should also be considered. Final decisions may still need to be individualized and based on clinicians’ discretion. This is part 2 of the statement.